References
- Sadri M, McMahon J, Parker A. Management of laryngeal dysplasia: a review. Eur Arch Otorhinolaryngol 2006; 263: 843–52
- Srinivas PR, Srivastava S, Hanash S, Wright GL JR. Proteomics in early detection of cancer. Clin Chem 2001; 47: 1901–11
- Adam BL, Vlahou A, Semmes OJ, Wright GL JR. Proteomic approaches to biomarker discovery in prostate and bladder cancers. Proteomics 2001; 1: 1264–70
- Von Eggeling F, Junker K, Fiedle W, Wollscheid V, Dürst M, Claussen U, et al. Mass spectrometry meets chip technology: a new proteomic tool in cancer research?. Electrophoresis 2001; 22: 2898–902
- Zhou L, Cheng L, Tao L, Jia X, Lu Y, Liao P. Detection of hypopharyngeal squamous cell carcinoma using serum proteomics. Acta Otolaryngol 2006; 126: 853–60
- Soltys SG, Le QT, Shi G, Tibshirani R, Giaccia AJ, Koong AC. The use of plasma surface-enhanced laser desorption/ionization time-of-flight mass spectrometry proteomic patterns for detection of head and neck squamous cell cancers. Clin Cancer Res 2004; 10: 4806–12
- Zhang YF, Wu DL, Guan M, Liu WW, Wu Z, Chen YM, et al. Tree analysis of mass spectral urine profiles discriminates transitional cell carcinoma of the bladder from noncancer patient. Clin Biochem 2004; 37: 772–9
- Skytt A, Thysell E, Stattin P, Stenman UH, Antti H, Wikström P. SELDI-TOF MS versus prostate specific antigen analysis of prospective plasma samples in a nested case-control study of prostate cancer. Int J Cancer 2007; 121: 615–20
- Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002; 359: 572–7
- Vlahou A, Laronga C, Wilson L, Gregory B, Fournier K, McGaughey D, et al. A novel approach toward development of a rapid blood test for breast cancer. Clin Breast Cancer 2003; 4: 203–9
- Lee IN, Chen CH, Sheu JC, Lee HS, Huang GT, Chen DS, et al. Identification of complement C3a as a candidate biomarker in human chronic hepatitis C and HCV-related hepatocellular carcinoma using a proteomics approach. Proteomics 2006; 6: 2865–73
- Zhukov TA, Johanson RA, Cantor AB, Clark RA, Tockman MS. Discovery of distinct protein profiles specific for lung tumors and pre-malignant lung lesions by SELDI mass spectrometry. Lung Cancer 2003; 40: 267–9
- Yu Y, Chen S, Wang LS, Chen WL, Guo WJ, Yan H, et al. Prediction of pancreatic cancer by serum biomarkers using surface-enhanced laser desorption/ionization-based decision tree classification. Oncology 2005; 68: 79–86
- Schwegler EE, Cazares L, Steel LF, Adam BL, Johnson DA, Semmes OJ, et al. SELDI-TOF MS profiling of serum for detection of the progression of chronic hepatitis C to hepatocellular carcinoma. Hepatology 2005; 41: 634–42
- Cheng L, Zhou L, Tao L, Zhang M, Cui J, Li Y. SELDI-TOF MS profiling of serum for detection of laryngeal squamous cell carcinoma and the progression to lymph node metastasis. J Cancer Res Clin Oncol 2008; 134: 769–76
- Plch J, Pár I, Navrátilová I, Bláhová M, Zavadil M. Long-term follow up study of laryngeal precancer. Auris Nasus Larynx 1998; 25: 407–12
- Hintz BL, Kagan A, Nussbaum H, Rao AR, Chan PY, Miles J. A. Watchful Waiting Policy” for in situ carcinoma of the vocal cords. Arch Otolaryngol 1981; 107: 746–51
- Strong MS. Laser management of premalignant lesions of the larynx. Can J Otolaryngol 1974; 3: 560–3
- Herrmann PC, Gillespie JW, Charboneau L, Bichsel VE, Paweletz CP, Calvert VS, et al. Mitochondrial proteome: altered cytochrome c oxidase subunit levels in prostate cancer. Proteomics 2003; 3: 1801–10
- Stafford ND, Condon LT, Rogers MJ, MacDonald AW, Atkin SL. The expression of somatostatin receptors 1 and 2 in benign, pre-malignant and malignant laryngeal lesions. Clin Otolaryngol Allied Sci 2003; 28: 314–19